FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2017-2027

  Guo, Miao ^a,b,c,d   Liu, Wei ^a,b,c   Serra, Stefano ^a,b,c   Asa, Sylvia L ^a,b,c   Ezzat, Shereen ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIB; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIC; FIBRONECTIN; GELATINASE B; GROWTH FACTOR RECEPTOR; KERATINOCYTE GROWTH FACTOR; MELANOMA ANTIGEN 3; PROTEIN P21; PROTEIN VARIANT; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CONTROLLED STUDY; EPITHELIUM CELL; EPITHELIUM STROMAL INTERACTION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; THYROID CANCER; TISSUE INTERACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; MICE; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 84860206461     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3985     Document Type: Article

References (42)

1. Brierley JD, Asa SL. Thyroid cancer. InGospodarowicz MK, O'Sullivan B, Sobin LH (eds.), Prognostic factors in cancer, 3 ed. New York, NY: Wiley-Liss Inc., 2006 pp. 119-22.
2. Asa SL, Bedard YC. Fine-needle aspiration cytology and histopathology. InClark OH, Noguchi S (eds.). Thyroid cancer. Diagnosis and treatment. St. Louis, MO: Quality Medical Publishing, Inc., 2000 pp. 39-104.
3. Boerner SL, Asa SL. Biopsy interpretation of the thyroid. Philadelphia, PA: Lippincott Williams & Wilkins. 2009.
4. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
5. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146:1145-53. (Pubitemid 40289303)
6. Ezzat S, Asa SL. FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis. Horm Metab Res 2005;37:355-60. (Pubitemid 41008769)
7. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49. (Pubitemid 40616112)
8. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-86. (Pubitemid 40616115)
9. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992;6:3362-9. (Pubitemid 23007101)
10. Ornitz DM, Zu J,Colvin JS,McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7. (Pubitemid 26195013)
11. Luo Y, Ye S, Kan M, McKeehan WL. Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb. J Cell Biochem 2006;97:1241-58.
12. Thisse B, Thisse C, Weston JA. Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev Dyn 1995;203:377-91.
13. Thisse B, Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 2005;287:390-402. (Pubitemid 41636772)
14. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev Biol 2001;231:47-62. (Pubitemid 32198386)
15. Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA. A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol Cell Biol 2003;23:9327-37. (Pubitemid 37499819)
16. Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008;68:8104-12.
17. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007;67:5461-70. (Pubitemid 46997287)
18. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
19. Zhu X, Lee K, Asa SL, Ezzat S. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 2007;170:1618-28. (Pubitemid 47339306)
20. Kondo T, Zhu X, Asa SL, Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007;13:4713-20. (Pubitemid 47294777)
21. Zhu X, Asa SL, Ezzat S. Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol 2010;176:2333-43.
22. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-43. (Pubitemid 30032102)
23. Bernard-Pierrot I, Ricol D, Cassidy A, Graham A, Elvin P, Caillault A, et al. Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene 2004;23:9201-11. (Pubitemid 40069690)
24. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, et al. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 2002;53:310-21. (Pubitemid 35398501)
25. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008;14:1984-96. (Pubitemid 351551107)
26. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62. (Pubitemid 350059681)
27. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5. (Pubitemid 41297230)
28. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3.
29. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4. (Pubitemid 47014500)
30. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, et al. Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 2007;9:R78.
31. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008;6:e108.
32. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991;6:69-663.
33. Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, et al. K-sam, an amplified gene in stomach cancer is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A 1990;87:5983-7.
34. Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am 2008;37:389-400, ix. (Pubitemid 351698083)
35. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997;57:5369-78. (Pubitemid 27516376)
36. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, et al. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci U S A 2001;98:11336-40. (Pubitemid 32928729)
37. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002;52:245-52. (Pubitemid 34791225)
38. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 1993;158:475-86. (Pubitemid 23243904)
39. Savagner P, Vallés AM, Jouanneau J, Yamada KM, Theiry JP. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994;5:851-62. (Pubitemid 24283766)
40. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-22. (Pubitemid 23220358)
41. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A 2006;103:14116-21. (Pubitemid 44452989)
42. Udagawa T, Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol 2010;10:369-74.